{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 404, "pageCount": 415, "prevPage": 403, "nextPage": 405, "slideType": "testimonial", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide uses a summary paragraph followed by a direct quote, highlighting the expert's negative sentiment.", "elementsJson": [ "paragraph", "quote_block" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/404", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-404", "components": [ { "bbox": { "h": 0.05, "w": 0.86, "x": 0.07, "y": 0.45 }, "kind": "callout", "text": "Edema and cardiac risk “is being underplayed”; surprised it got FDA approval; don't plan to prescribe it much; “even more careful” after our interview", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f39eee43-24f0-4a3a-8008-85d0edde1a3e", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "callout", "text": "The risks are real and significant, and probably underplayed to some degree, and the benefit is mild at best...I am a little bit surprised about the approval", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2b7-e2318fb0647d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "paragraph", "text": "The endocrinologist indicated that he was surprised at FDA approval; that edema and cardiac risks are “real and significant” and “being underplayed”; that the drug is basically useless; that “I just don’t think I’m going to be turning to this very often”; and that our interview only intensified his sense of caution – ““I think that the severity of edema and cardiac risk probably is being underplayed. The risks are real and significant, and probably underplayed to some degree, and the benefit is mild at best...I am a little bit surprised about the approval”; “this is not a drug that is going to be a game-changer”; “the simple fact is, I would, now that we've had this conversation, I think I'm going to be even more careful about my patient selection, which I probably always was to some degree, but even more so now.”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "2e898ac5-4958-4e08-a1a1-59d77c7b6da0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.86, "x": 0.07, "y": 0.51 }, "kind": "quote", "text": "“I think that the severity of edema and cardiac risk probably is being underplayed. The risks are real and significant, and probably underplayed to some degree, and the benefit is mild at best...I am a little bit surprised about the approval, that it was able to be approved. I get that there are no medicines currently approved in the space. And so, having anything is better than having nothing is the thought process there. But this is not a drug that is going to be a game-changer in this space. I think that there are so many different medicines on the appetite side of the ledger, on the weight management side of things in development, that I just don't think that I'm going to be turning to this very often. I was planning on trying it on at least somebody to get some clinical experience with it. I was not involved in any of these research studies. I don't have a lot of experience with the medicine, obviously in Prader-Willi, and I have my small cohort of folks who have used it for hypoglycemia. But the simple fact is, I would, now that we've had this conversation, I think that I'm going to be even more careful about my patient selection, which I probably always was to some degree, but even more so now.” - Endocrinologist in TX, private practice with 5 PWS patients", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3ad10acd-718a-4f76-b067-8b6920fa120b", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“I think that the severity of edema and cardiac risk probably is being underplayed. The risks are real and significant, and probably underplayed to some degree, and the benefit is mild at best...I am a little bit surprised about the approval, that it was able to be approved. I get that there are no medicines currently approved in the space. And so, having anything is better than having nothing is the thought process there. But this is not a drug that is going to be a game-changer in this space. I think that there are so many different medicines on the appetite side of the ledger, on the weight management side of things in development, that I just don't think that I'm going to be turning to this very often. I was planning on trying it on at least somebody to get some clinical experience with it. I was not involved in any of these research studies. I don't have a lot of experience with the medicine, obviously in Prader-Willi, and I have my small cohort of folks who have used it for hypoglycemia. But the simple fact is, I would, now that we've had this conversation, I think I'm going to be even more careful about my patient selection, which I probably always was to some degree, but even more so now.” — Endocrinologist in TX, private practice with 5 PWS patients", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2b7-e42de00f6f14", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "04ce796a-63dc-40c5-ab86-764138eff1fb", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }